FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a crystalline form A and a crystalline form B of a compound represented by formula (I), and to an application thereof in the production of medicinal products for treating HBV.
EFFECT: production of new crystalline forms of the compound represented by the formula (I), applicable in the production of medicinal products for treating HBV.
13 cl, 8 dwg, 10 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING CRYSTALLINE FORM OF HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | 2020 |
|
RU2823673C1 |
| COMPOUND OF FGFR INHIBITOR IN SOLID FORM AND METHOD OF ITS PREPARATION | 2020 |
|
RU2810067C2 |
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
| TARTRATE 3-((1R,3R)-1-(2,6-DIFLUORINE-4-((1-(3- FLUOROPROPYL)AZETIDINE-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-b]INDOLE-2-YL)-2,2-DIFLUOROPROPANE-1-OL, ITS SOLID FORMS, METHOD OF ITS PREPARATION AND THEIR APPLICATION | 2019 |
|
RU2809220C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| METHOD FOR PREPARING NO-DONOR COMPOUNDS, SUCH AS NO-DONOR DICLOFENAC | 2003 |
|
RU2322434C2 |
| AMORPHOUS DERIVATIVE OF PYRROLIDINE AS PPAR AGONIST AND METHOD FOR PRODUCTION THEREOF | 2018 |
|
RU2749056C1 |
| PHARMACEUTICALLY ACCEPTABLE THYMODEPRESSIN SALTS AND METHOD OF OBTAINING THEREOF | 2007 |
|
RU2536685C2 |
| CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING N-HETEROCYCLIC FIVE-MEMBERED RING, ITS PHARMACEUTICAL COMPOSITION AND USE | 2019 |
|
RU2802259C2 |
| METHOD FOR OBTAINING FLUTICASONE PROPIONATE OBTAINING, PARTICULARLY POLYMORPHOUS FORM 1 | 2003 |
|
RU2333218C2 |
